
CGON Stock Forecast & Price Target
CGON Analyst Ratings
Bulls say
CG Oncology Inc's cretostimogene grenadenorepvec is positioned for a promising market entry, with projected launch sales commencing in 2026 and anticipated growth to approximately $2.6 billion by 2034, highlighting the potential for premium pricing that could bolster long-term revenue expectations. The product's favorable efficacy and durability, as evidenced by recent clinical data, underscore its strong market differentiation and its potential to address significant unmet needs in bladder cancer treatment, especially for high-risk BCG-unresponsive NMIBC patients. Furthermore, the company's readiness for commercialization, along with an estimated approval timeline supporting market entry by late 2026, reinforces confidence in its operational execution and the potential expansion into broader patient populations.
Bears say
CG Oncology's negative outlook is primarily influenced by concerns regarding the potential for insufficient differentiation of its candidate, cretostimogene grenadenorepvec, in the competitive oncology market, where prior products like Zaltrap have failed due to lack of advantage despite higher pricing. The company faces significant risks related to delayed trial readouts, slower enrollment, and any potential negative regulatory outcomes that could hinder commercialization efforts and restrict market opportunities. Additionally, the potential for challenges to intellectual property could further damage CG Oncology's competitive stance in the biopharmaceutical landscape, impacting investor sentiment.
This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.
CGON Analyst Forecast & Price Prediction
Start investing in CGON
Order type
Buy in
Order amount
Est. shares
0 shares